Biopharmaceutical company Kymab has announced a three-year, $9 million grant from the Bill & Melinda Gates Foundation to accelerate the development of novel vaccines and therapeutics for infectious diseases, including HIV.
The grant will support the company's efforts to develop treatments and vaccines for infectious disease using its Kymouse monoclonal antibody platform. The foundation will have the rights to develop and distribute these products to low-income countries, while Kymab will retain rights to commercialize the products in developed countries.
Kymab, which is based in the United Kingdom, has been working with the foundation and its partners since 2014 on programs related to diseases, including malaria, HIV, and typhoid, that collectively result in more than a million deaths annually. In addition to the new investment in the company's research, the foundation also invested $30 million in Series B and Series C financing for the company that helped support development of the Kymouse platform.
"We are delighted that the Bill and Melinda Gates Foundation has extended our collaboration," said Kymab CEO David Chiswell. "We have built a strong infectious disease program under Paul Kellam, our vice president of vaccines and infectious disease, and we share the foundation's aims to tackle diseases that have significant impact in some of the world’s poorest countries. We look forward to continuing to use our ability to produce human antibodies using our Kymouse technology to support and accelerate vaccine and therapeutic antibody development for global diseases."